Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab and Atezolizumab in Advanced Cancer
NCT02543645Phase 1Terminated
- Sponsor
- Celldex Therapeutics
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of varlilumab in melanoma, renal cell carcinoma (RCC), triple-negative breast cancer (TNBC) and 3 more, sponsored by Celldex Therapeutics. Primary endpoint: Safety and tolerability of varlilumab in combination with atezolizumab at 70 days. Started Oct 2015; status: terminated.
02
Drugs
varlilumab
03
Conditions
melanomarenal cell carcinoma (RCC)triple-negative breast cancer (TNBC)bladder cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02543645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543645.